[ad_1]
India
oi-Prakash KL
New Delhi, Feb 19: Hyderabad-based Bharat Biotech mentioned its COVID-19 vaccine Covaxin will likely be evaluated as a vaccine candidate for the illness in the US, the corporate on Saturday acknowledged in a press release.
“Ocugen, Inc (NASDAQ: OCGN) introduced that the US Meals and Drug Administration (FDA) has lifted its scientific maintain on the Firm’s Investigational New Drug software (IND) to guage the COVID-19 vaccine candidate, BBV152, often known as Covaxin outdoors the US. Ocugen, Inc is co-developing Bharat Biotech’s Covaxin vaccine candidate for COVID-19 in USA and Canada,” Bharat Biotech mentioned.
Earlier, the Ministry of Well being and Household Welfare had knowledgeable that Covaxin has been granted approval for emergency use in 13 international locations as of January 31, 2022.
80 laptop of India’s adults totally vaccinated towards COVID-19: Mandaviya
In the meantime, Union Well being Minister Mansukh Mandaviya mentioned that 80 per cent of India’s grownup inhabitants has been totally vaccinated towards COVID-19. The cumulative variety of COVID-19 vaccine doses administered within the nation has crossed 175 crore, in accordance with official knowledge.
India has crossed the historic milestone of administering each doses of coronavirus vaccine to 80 per cent of its grownup inhabitants, Mandaviya mentioned in a tweet. “With the mantra of ‘sabka prayas’ beneath the management of PM @NarendraModi ji, the nation is transferring at a quick tempo in direction of 100 per cent immunisation,” he mentioned.
In accordance with official knowledge, round 96.5 per cent of the nation’s grownup inhabitants has been administered the primary dose of COVID-19 vaccine. Over 2 crore adolescents within the 15-18 age group have obtained each doses of COVID-19 vaccine, the federal government mentioned. Companies
-
COVID-19 norms violation: BJP chief will get summons
-
Germany relaxes COVID measures, at the same time as dangers stay
-
WHO says new COVID circumstances drop by 19 per cent globally, deaths secure
-
India experiences 30,757 contemporary COVID circumstances; 514 extra deaths
-
COVID digest: BioNTech unveils cell vaccine models
-
COVID’s largest losers: Youngsters and youths
-
Centre writes to states, UTs, asks to finish Covid restrictions
-
India provides 30,615 new COVID-19 circumstances, 514 deaths
-
Covid can grow to be endemic solely after 4 weeks of constantly low circumstances: Virologist
-
Organic E’s COVID-19 vaccine will get nod; Centre prone to obtain first provide of Corbevax right now
-
India provides 27,409 COVID-19 circumstances, 347 fatalities
-
After practically 2 years, pre-schools, anganwadis to reopen in Gujarat from Feb 17
[ad_2]
Source link
